Dermaluxe Advanced Aesthetics Ltd 16319845 false 2025-03-17 2026-03-31 2026-03-31 The principal activity of the company is that of other human health activities. Digita Accounts Production Advanced 6.30.9574.0 true 16319845 2025-03-17 2026-03-31 16319845 2026-03-31 16319845 bus:SmallEntities 2025-03-17 2026-03-31 16319845 bus:AuditExemptWithAccountantsReport 2025-03-17 2026-03-31 16319845 bus:FilletedAccounts 2025-03-17 2026-03-31 16319845 bus:SmallCompaniesRegimeForAccounts 2025-03-17 2026-03-31 16319845 bus:RegisteredOffice 2025-03-17 2026-03-31 16319845 bus:Director1 2025-03-17 2026-03-31 16319845 bus:PrivateLimitedCompanyLtd 2025-03-17 2026-03-31 16319845 countries:England 2025-03-17 2026-03-31 iso4217:GBP xbrli:pure

Registration number: 16319845

Dermaluxe Advanced Aesthetics Ltd

Unaudited Filleted Abridged Financial Statements

for the Period from 17 March 2025 to 31 March 2026

 

Dermaluxe Advanced Aesthetics Ltd

Contents

Abridged Balance Sheet

1

Notes to the Unaudited Abridged Financial Statements

2 to 3

 

Dermaluxe Advanced Aesthetics Ltd

(Registration number: 16319845)
Abridged Balance Sheet as at 31 March 2026

Note

2026
£

Current assets

 

Cash at bank and in hand

 

100

Capital and reserves

 

Called up share capital

4

100

Shareholders' funds

 

100

For the financial period ending 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

All of the company’s members have consented to the preparation of an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 17 June 2026
 

.........................................
Mr D Philpott
Director

 

Dermaluxe Advanced Aesthetics Ltd

Notes to the Unaudited Abridged Financial Statements for the Period from 17 March 2025 to 31 March 2026

1

General information

The company is a private company limited by share capital, incorporated in England.

The address of its registered office is:
275 Church Road
Lytham St Annes
Lancashire
FY8 3NP

These financial statements were authorised for issue by the director on 17 June 2026.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These abridged financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

3

Staff numbers

The average number of persons employed by the company (including the director) during the period, was 0.

 

Dermaluxe Advanced Aesthetics Ltd

Notes to the Unaudited Abridged Financial Statements for the Period from 17 March 2025 to 31 March 2026

4

Share capital

Allotted, called up and fully paid shares

2026

No.

£

Ordinary A Shares of £1 each

50

50

Ordinary B Shares of £1 each

50

50

100

100